Disclosed is a melanoma vaccine comprising: at least one dendritic cell from a subject that has melanoma； wherein the at least one dendritic cell had been contacted in vitro with at least one melanoma tumour cell from the same subject, wherein the at least one melanoma tumour cell is non-dividing and not treated in vitro with interferon-gamma (IFN-gamma) or an IFN-gamma mimetic, and at least 60% of the melanoma tumour cells are autophagic, and non-apoptotic. Also disclosed is the use of the above-described melanoma vaccine in the manufacture of a medicament for stimulating an immune response against a melanoma-specific antigen in a subject with melanoma.
